RNU6-1161P

Across TCGA pan-cancer cohorts, RNU6-1161P RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RNU6-1161P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU6-1161P RNA is repressed in tumor relative to normal tissue. In most cancer types RNU6-1161P is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, STAD, and LUAD are the cancer types where RNU6-1161P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1161P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.410	<.001	10	view →
STAD	Male	All	+1.549	<.001	9	view →
LUAD	Female	II,III,IV	+1.934	<.001	8	view →
COAD	Female	All	+0.823	<.001	8	view →
KICH	Male	All	−2.245	<.001	7	view →
LUSC	Male	II,III,IV	+1.714	<.001	6	view →
BRCA	Female	II,III,IV	−0.665	<.001	6	view →
HNSC	All	All	+0.759	.001	5	view →
PAAD	All	All	+2.112	.022	2	view →
PRAD	All	All	−0.551	.001	2	view →
CHOL	All	All	+1.301	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RNU6-1161P–KIRC

Open the KIRC breakdown →